Targets › SCFA
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on SCFA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Center Eugene Marquis | EXL01 Single strain Faecalibacterium prausnitzii to modulate gut microbiota and enhance immunoth | SCFA | Phase 2 | Hepatocellular Carcinoma | Dec 2026 |
Hepatocellular Carcinoma (1)
small molecule (1)
Center Eugene Marquis (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.